CytoArm｜BsAb Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment
Innovative BsAb Armed-T therapy platform utilizes non-viral bi-functional antibodies (BsAb) to empower T cells.
Innovative BsAb Armed-T therapy platform utilizes non-viral bi-functional antibodies (BsAb) to empower T cells.
CytoArm, founded in 2020, is a biotech startup that focuses on developing next-generation T cell therapy known as Armed-T cell. The company's innovative BsAb Armed-T therapy platform utilizes non-viral bi-functional antibodies (BsAb) to empower T cells, providing a novel approach to cancer treatment.
The team at CytoArm is composed of experts in both business and medical fields, bringing comprehensive experience to the development of novel T cell therapy for clinical treatment. Their goal is to address untreatable diseases through advanced T cell therapy, leveraging cutting-edge technology and expertise.
With a strong focus on revolutionizing cancer treatment, CytoArm presents an attractive opportunity for venture capital investment. The potential of their innovative therapy platform and the expertise of the team make them a compelling prospect for investment in 2021.
There is no investment information
No recent news or press coverage available for CytoArm｜BsAb Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment.
We care about your data, and we'd love to use cookies make your experience better.